1. Home
  2. TCMD vs ANNX Comparison

TCMD vs ANNX Comparison

Compare TCMD & ANNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Tactile Systems Technology Inc.

TCMD

Tactile Systems Technology Inc.

HOLD

Current Price

$29.21

Market Cap

300.1M

Sector

Health Care

ML Signal

HOLD

Logo Annexon Inc.

ANNX

Annexon Inc.

HOLD

Current Price

$5.01

Market Cap

334.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
TCMD
ANNX
Founded
1995
2011
Country
United States
United States
Employees
N/A
N/A
Industry
Medical/Dental Instruments
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
300.1M
334.1M
IPO Year
2016
2020

Fundamental Metrics

Financial Performance
Metric
TCMD
ANNX
Price
$29.21
$5.01
Analyst Decision
Buy
Strong Buy
Analyst Count
4
6
Target Price
$23.25
$16.50
AVG Volume (30 Days)
332.5K
2.9M
Earning Date
02-17-2026
11-10-2025
Dividend Yield
N/A
N/A
EPS Growth
18.66
N/A
EPS
0.77
N/A
Revenue
$311,513,000.00
N/A
Revenue This Year
$11.31
N/A
Revenue Next Year
$8.83
N/A
P/E Ratio
$38.69
N/A
Revenue Growth
9.28
N/A
52 Week Low
$8.61
$1.29
52 Week High
$30.24
$5.66

Technical Indicators

Market Signals
Indicator
TCMD
ANNX
Relative Strength Index (RSI) 66.16 61.69
Support Level $29.02 $4.94
Resistance Level $29.92 $5.48
Average True Range (ATR) 0.92 0.28
MACD -0.22 -0.03
Stochastic Oscillator 60.90 34.93

Price Performance

Historical Comparison
TCMD
ANNX

About TCMD Tactile Systems Technology Inc.

Tactile Systems Technology Inc is a medical technology company. The company is engaged in developing and providing medical devices for the treatment of chronic diseases. The firm's proprietary platform flexitouch system provides a home-based solution for lymphedema patients. The entire system is another home solution for patients with chronic swelling and actitouch system for chronic venous insufficiency patients that may be worn throughout the day.

About ANNX Annexon Inc.

Annexon Inc is a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, brain, and eye. Its pipeline is based on its platform technology addressing well-researched classical complement-mediated autoimmune and neurodegenerative disease processes, both of which are triggered by aberrant activation of C1q. Its pipeline of product candidates is designed to block the activity of C1q and the entire classical complement pathway in a broad set of complement-mediated diseases. Its product candidates are ANX005, for autoimmune & neurodegenerative disorders; ANX007, for neurodegenerative ophthalmic disorders; ANX1502 for Oral small molecule; and ANX009, for systemic autoimmune diseases.

Share on Social Networks: